| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
108,674,000 |
| Market
Cap: |
72.81(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0.2298 - $2.97 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : 9.4 |
| Insider 3/6 Months : 10 |
|
| Guru Rank Number : 707 |
| Guru Rank Value : 1.9 |
| Guru Occurances : 1 |
|
|
|
|
|
| |
|
Company Profile Atara Biotherapeutics is engaged in T-cell immunotherapy, using its allogeneic Epstein-Barr virus (EBV) T-cell platform to develop therapies for patients with diseases, including tumors, hematologic cancers and autoimmune disease. Co.'s platform utilizes the biology of EBV T cells and has the capability to treat a range of EBV-driven diseases or other diseases through incorporation of engineered chimeric antigen receptors or T-cell receptors. Co.'s T-cell immunotherapy program, tab-cel® (tabelecleucel), is partnered with Pierre Fabre Medicament and is in Phase 3 development for patients with EBV-driven post-transplant lymphoproliferative disease.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
816,825 |
816,825 |
816,825 |
| Total Buy Value |
$0 |
$194,885 |
$194,885 |
$194,885 |
| Total People Bought |
0 |
3 |
3 |
3 |
| Total Buy Transactions |
0 |
4 |
4 |
4 |
| Total Shares Sold |
56,192 |
121,276 |
273,751 |
412,845 |
| Total Sell Value |
$40,460 |
$65,778 |
$342,884 |
$1,024,948 |
| Total People Sold |
5 |
6 |
7 |
9 |
| Total Sell Transactions |
5 |
11 |
22 |
41 |
| End Date |
2024-02-04 |
2023-11-03 |
2023-05-05 |
2022-05-05 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Newell Joe |
Chief Operations Officer |
• – – |
2020-04-06 |
4 |
AS |
$7.94 |
$5,217 |
D/D |
(657) |
125,484 |
|
50% |
|
| Koppikar Utpal |
Chief Financial Officer |
• – – |
2020-03-27 |
4 |
AS |
$9.17 |
$16,754 |
D/D |
(1,827) |
137,330 |
|
30% |
|
| Newell Joe |
Chief Operations Officer |
• – – |
2020-03-27 |
4 |
AS |
$9.17 |
$25,126 |
D/D |
(2,740) |
126,141 |
|
30% |
|
| Yarema Kristin |
Chief Commercial Officer |
• – – |
2020-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
55,000 |
55,000 |
|
- |
|
| Koppikar Utpal |
Chief Financial Officer |
• – – |
2020-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
66,875 |
139,157 |
|
- |
|
| Touchon Pascal |
President and CEO |
• • – |
2020-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
150,000 |
280,174 |
|
- |
|
| Newell Joe |
Chief Operations Officer |
• – – |
2020-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
75,000 |
128,881 |
|
- |
|
| Koppikar Utpal |
Chief Financial Officer |
• – – |
2020-02-06 |
4 |
AS |
$14.21 |
$25,308 |
D/D |
(1,781) |
72,282 |
|
-25% |
|
| Newell Joe |
Chief Tech. Operations Officer |
• – – |
2020-02-06 |
4 |
AS |
$14.21 |
$58,503 |
D/D |
(4,117) |
53,881 |
|
-25% |
|
| Touchon Pascal |
President and CEO |
• • – |
2020-01-24 |
4 |
D |
$13.62 |
$134,838 |
D/D |
(9,900) |
130,174 |
|
- |
|
| Newell Joe |
Chief Tech. Operations Officer |
• – – |
2019-09-27 |
4 |
S |
$13.51 |
$47,285 |
D/D |
(3,500) |
57,998 |
|
- |
|
| Seidenberg Beth C |
Director |
– • – |
2019-06-27 |
4 |
A |
$0.00 |
$0 |
D/D |
4,000 |
19,189 |
|
- |
|
| Dobmeier Eric |
Director |
– • – |
2019-06-27 |
4 |
A |
$0.00 |
$0 |
D/D |
4,000 |
20,000 |
|
- |
|
| Dobmeier Eric |
Director |
– • – |
2019-06-27 |
4 |
B |
$19.50 |
$39,000 |
D/D |
2,000 |
16,000 |
2.39 |
- |
|
| Heiden William K |
Director |
– • – |
2019-06-27 |
4 |
A |
$0.00 |
$0 |
D/D |
4,000 |
12,500 |
|
- |
|
| Fust Matthew K |
Director |
– • – |
2019-06-27 |
4 |
A |
$0.00 |
$0 |
D/D |
4,000 |
25,854 |
|
- |
|
| Gallagher Carol Giltner |
Director |
– • – |
2019-06-27 |
4 |
A |
$0.00 |
$0 |
D/D |
4,000 |
92,818 |
|
- |
|
| Baynes Roy D. |
Director |
– • – |
2019-06-27 |
4 |
A |
$0.00 |
$0 |
D/D |
4,000 |
4,000 |
|
- |
|
| Touchon Pascal |
President and CEO |
• • – |
2019-06-24 |
4 |
A |
$0.00 |
$0 |
D/D |
140,074 |
140,074 |
|
- |
|
| Ciechanover Isaac E. |
Chief Executive Officer |
• • – |
2019-05-30 |
4 |
AS |
$22.72 |
$67,926 |
I/I |
(2,925) |
290,687 |
|
- |
|
| Ciechanover Isaac E. |
Chief Executive Officer |
• • – |
2019-05-29 |
4 |
AS |
$22.85 |
$67,163 |
I/I |
(2,925) |
293,612 |
|
- |
|
| Berger Dietmar |
Global Head of R&D |
• – – |
2019-05-07 |
4 |
D |
$33.46 |
$144,614 |
D/D |
(4,322) |
85,678 |
|
- |
|
| Newell Joe |
Chief Tech. Operations Officer |
• – – |
2019-05-06 |
4 |
AS |
$35.00 |
$52,500 |
D/D |
(1,500) |
61,498 |
|
- |
|
| Newell Joe |
Chief Tech. Operations Officer |
• – – |
2019-05-06 |
4 |
OE |
$20.40 |
$30,600 |
D/D |
1,500 |
62,998 |
|
- |
|
| Ciechanover Isaac E. |
Chief Executive Officer |
• • – |
2019-04-26 |
4 |
AS |
$33.47 |
$130,533 |
I/I |
(3,900) |
304,337 |
|
- |
|
731 Records found
|
|
Page 8 of 30 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
0.02 (3.03%) 
